EUCTR2007-003677-10-GB进行中（未招募）不适用
A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combinations of ramipril/amlodipine (10/10mg) and aliskiren/amlodipine (300/10mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10mg. - N.A.
ovartis Pharmaceuticals UK Ltd0 个研究点开始时间: 2008年3月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Outpatients 18-70 years of age and older.
- •2.Male or female patients are eligible.
- •3.Patients with a diagnosis of hypertension:
- •Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a MSBBP = 140 mmHg and < 180 mmHg at Visit 1.
- •Patients treated with antihypertensive monotherapy medications must have a MSSBP = 130 mmHg and < 180 mmHg at Visit 1.
- •Patients taking amlodipine monotherarpy with a MSSBP = 130 mmHg and < 180. For patients taking amlodipine 5mg visits 1 and 2 can be combined and for patients taking amlodipine 10mg visits 1 and 3 can be combined (vist 2 not necessary).
- •4.All patients must have a MSSBP = 140 mmHg and < 180 mmHg at Visit 3, the end of the amlodipine run-in period.
- •5.Patients with a diagnosis of Metabolic Syndrome (Definition of International Diabetes Federation – IDF 2006)
- •- Central obesity - waist circumference (cm)
- •South Asian / Chinese / Japanese / Central+South American =90cm ?, = 80cm ?
- •Europid / Subsaharan African / Middle East =94cm ? , =80cm ?
- •- Fasting plasma glucose of =5.6mmol/l
- •- Triglycerides = 1.7 mmol/l (or on therapy)
- •- HDL cholesterol < 1.03 mmol/l males, < 1.29 mmol/l females (or on therapy)
- •6.Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with any of the following at Visit 1, Visit 2, Visit 3 (unless otherwise stated) will be excluded from participation in the study.
- •1.Previously treated in an aliskiren study and who qualified to be randomized or enrolled into the active drug treatment period.
- •2.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (= 5 mIU/ml).
- •3.Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
- •4.Patients currently on antihypertensive medication(s) that require tapering of > 7 days at Visit 1.
- •5.Severe hypertension (an office cuff MSDBP = 115 mmHg and/or MSSBP = 180 mmHg).
- •6.History or evidence of a secondary form of hypertension.
- •7.Known Keith-Wagener grade III or IV hypertensive retinopathy.
- •8.Previous or current diagnosis of heart failure (NYHA Class II-IV).
- •9.History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).
- •10.Serum sodium < 135 mEq/ L (mmol/L) at Visit 1, if confirmed on repeat sample.
- •11.Serum potassium < 3.5 mEq/L (mmol/L) or = 5.3 mEq/L (mmol/L) at Visit 1, if confirmed on repeat sample.
- •12.Type 1 diabetes mellitus.
- •13.Type 2 diabetes mellitus if change in oral hypoglycaemic in previous 3 months..
- •14.Current angina pectoris requiring pharmacological therapy.
- •15.Second or third degree heart block without a pacemaker.
- •16.Atrial fibrillation or atrial flutter at Visit 1, or potentially life threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1.
- •17.Clinically significant valvular heart disease.
- •18.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:
- •History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection.
- •History of active inflammatory bowel disease during the 12 months prior to Visit 1.
- •Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal bleeding during the 3 months prior to Visit 1.
- •Any history of pancreatic injury, pancreatitis, or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase during the 12 months prior to Visit 1.
- •Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3 x ULN at Visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt.
研究者
相似试验
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension - non aplicableHypertensionEUCTR2004-002252-33-ESovartis Farmacéutica S.A672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertensioHypertensionEUCTR2004-002252-33-DEovartis Pharma Services AG672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.hypertensionEUCTR2008-007831-41-GBovartis Pharma Services AG790
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2008-007831-41-SKovartis Pharma Services AG790
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients with 24-hour ambulatory blood pressure measurement after 1 week of treatment withdrawal.hypertensionEUCTR2008-007831-41-HUovartis Pharma Services AG790